$PRVA

Mountcastle David sold $680K of PRVA

Mountcastle David (EVP & Chief Financial Officer) sold 24,734 shares of Privia Health Group, Inc. (PRVA) at $27.50 ($0.68M total) on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mountcastle David
Published Jul 7, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRVA
Neutral
high confidence
Mentioned
$PRVA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRVANeutralLow
01

Why it matters

The newest fact is the disclosed sale size ($680,185) and post-transaction holdings (186,728 shares). This can marginally influence sentiment but does not introduce new company fundamentals.

02

Market read

Primarily a sentiment/positioning datapoint for PRVA; likely limited trading impact absent other catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, contracts, or earnings, the disclosure is mostly informational rather than decision-driving.

Relevance 4/10Novelty 3/10Timing: Filed July 7 after-hours; reflects insider sale executed July 2.

Background

The article is an SEC Form 4 insider transaction: Mountcastle David (EVP & CFO) sold shares of Privia Health Group, Inc. under a 10b5-1 plan.

Company-level read

Ticker impact

$PRVANeutralHigh confidence
Context

Privia Health Group CFO David Mountcastle sold 24,734 shares in an open-market transaction under a 10b5-1 plan on July 2.

Expected impact

Low near-term impact; any reaction is likely limited to short-lived sentiment around insider selling.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, and it provides no new operating, guidance, or regulatory information.

Market effects

No direct sector read-through; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be mechanically scheduled rather than a forward-looking negative signal.

Key entities

  • Privia Health Group, Inc.

    Subject of the Form 4 insider transaction; CFO David Mountcastle sold shares under a 10b5-1 plan.

  • David Mountcastle

    EVP & CFO who executed the open-market sale disclosed in the Form 4.

Related articles

$PRVAHighAI 9/10

Privia Health Group, Inc. (PRVA): Results of Operations and Financial Condition

Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for